Skip to main content
Have a personal or library account? Click to login
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors Cover

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors

Radiology and Oncology
Volume 49 (2015): Issue 4 (December 2015)
By: ,  ,  ,  ,  ,  ,  ,   and    
Open Access
|Nov 2015
References

References

  1. 1. Ulisse S, Baldini E, Sorrenti S, D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy.2009;32-71.
    Open DOISearch in Google Scholar
  2. 2. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).1998;893-906.
    Open DOISearch in Google Scholar
  3. 3. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication.2000;621-8.
    Open DOISearch in Google Scholar
  4. 4. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator.2002;932-43.
    Open DOISearch in Google Scholar
  5. 5. Rosenberg S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective.2003;4p.
    Open DOISearch in Google Scholar
  6. 6. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.2003;1529-43.
    Open DOISearch in Google Scholar
  7. 7. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in 8377 breast cancer patients.2002;116-28.
    Open DOISearch in Google Scholar
  8. 8. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. for the German chemo N0 study group. Randomyzed adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.2001;913-20.
    Open DOISearch in Google Scholar
  9. 9. Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer.2009;43-66.
    Open DOISearch in Google Scholar
  10. 10. Takac I, Cufer T, Gorisek B, Cas-Sikosek N, Bali R, Bosilj D, et al. [The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer]. [Slovenian].2011;405-12.
    Search in Google Scholar
  11. 11. Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.1988;531-3.
    Open DOISearch in Google Scholar
  12. 12. Jänicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer.1989;1049
    Open DOISearch in Google Scholar
  13. 13. Foekens JA, Schmitt M, Van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.1992;6101-5.
    Search in Google Scholar
  14. 14. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.1994;1648-58.
    Open DOISearch in Google Scholar
  15. 15. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.2000;636-43.
    Search in Google Scholar
  16. 16. Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.2011;532-9.
    Open DOISearch in Google Scholar
  17. 17. Eljuga D, Razumovic JJ, Bulic K, Petrovecki M, Draca N, Bulic SO. Prognostic importance of PAI-1 in node negative breast cancer patients - results after 10 years of follow up.2011;290-4.
    Open DOISearch in Google Scholar
  18. 18. Gazic B, Pizem J, Bracko M, Cufer T, Borstnar S, Pohar-Marinsek Z, et al. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.2008;294-302.
    Open DOISearch in Google Scholar
  19. 19. Borstnar S, Sadikov A, Mozina B, Cufer T. High levels of uPA and PAI-1 predict a good response to anthracyclines.2010;615-24.
    Open DOISearch in Google Scholar
  20. 20. Xu FJ, Stack S, Boyer C, O’Briant K, Whitaker R, Mills GB, et al. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.1997;1629-34.
    Search in Google Scholar
  21. 21. Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP. ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells.2000;666-74.
    Open DOISearch in Google Scholar
  22. 22. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.1998;28238-46.
    Open DOISearch in Google Scholar
  23. 23. Arboleda J, Slamon DJ. Heregulin induced cell invasion of HER-2/neu transfected breast cancer cell line is mediated through activation of the phosphatidylinositol 3-kinase/AKT2 pathway.; 1999 May 12.-16. p. 11.
    Search in Google Scholar
  24. 24. Berney CR, Yang J, Fisher RJ, Russell PJ, Crowe PJ. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression.1998;47-54.
    Search in Google Scholar
  25. 25. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.2000;2201-9.
    Open DOISearch in Google Scholar
  26. 26. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer.1985;139-66.
    Open DOISearch in Google Scholar
  27. 27. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.1997;285-96.
    Open DOISearch in Google Scholar
  28. 28. Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.2003;1022-8.
    Open DOISearch in Google Scholar
  29. 29. Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, et al. HER2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.2001;2448-57.
    Search in Google Scholar
  30. 30. Decker T, Hungermann D, Böcker W. [Prognostic and predictive factors of invasive breast cancer: update 2009]. [German].2009;49-55.
    Open DOISearch in Google Scholar
  31. 31. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds.. Edinburgh: Churchill Livingstone; 1987. p. 300-11.
    Search in Google Scholar
  32. 32. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: six-year median follow-up.1999;419-26.
    Open DOISearch in Google Scholar
  33. 33. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.1997;306-11.
    Open DOISearch in Google Scholar
  34. 34. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.1999;147-57.
    Open DOISearch in Google Scholar
  35. 35. Cufer T, Vrhovec I, Borštnar S. Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival.2002;33-41.
    Open DOISearch in Google Scholar
  36. 36. Cufer T, Vrhovec I, Borštnar S. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 and PAI-2 in operable breast cancer.2003;106-15.
    Open DOISearch in Google Scholar
  37. 37. Cufer T. Clinical utility of serine proteases in breast cancer.2004;85-92.
    Search in Google Scholar
  38. 38. Ferrero-Poüs M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.2000;4745-54.
    Search in Google Scholar
  39. 39. Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, et al. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.2008;168-77.
    Open DOISearch in Google Scholar
  40. 40. Harbeck N, Kates R, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.2002;1000-7.
    Open DOISearch in Google Scholar
  41. 41. Esteva FJ, Hortobagyi GN. Prognostic markers in early breast cancer.2004;109-18.
    Open DOISearch in Google Scholar
  42. 42. De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, et al. Breast Cancer Study Group of the Institut Curie. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.2009;1475-82.
    Search in Google Scholar
  43. 43. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis.2006;262-72.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/raon-2014-0049 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 357 - 364
Submitted on: Aug 3, 2014
Accepted on: Nov 11, 2014
Published on: Nov 27, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
urokinase plasminogen activator,
plasminogen activator inhibitor,
breast cancer,
prognostic factor
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Maja Lampelj, Darja Arko, Nina Cas-Sikosek, Rajko Kavalar, Maja Ravnik, Barbara Jezersek-Novakovic, Sarah Dobnik, Nina Fokter Dovnik, Iztok Takac, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 4 (December 2015)
Previous article
Next article